Historical Grant

MRFF International Clinical Trial Collaborations Grant 2026 (GO8232): Historical Reference

Historical reference for the one-round 2026 MRFF International Clinical Trial Collaborations grant (GO8232), which closed on 16 September 2026. NHMRC has not announced another round on the official opportunity page.

FindMyMoney.App
Published by FindMyMoney.App
Official source: National Health and Medical Research Council (NHMRC)
đź’° Funding Up to AUD 3,000,000 per grant; up to AUD 13,000,000 available for the opportunity
đź“… Deadline Historical reference
📍 Location Australia
🏛️ Source National Health and Medical Research Council (NHMRC)

MRFF International Clinical Trial Collaborations Grant 2026 (GO8232): Historical Reference

The Medical Research Future Fund (MRFF) International Clinical Trial Collaborations Grant Opportunity (GO8232) was a one-round Australian Government grant for teams proposing Australian participation in an international investigator-initiated clinical trial. The application period has ended. NHMRC’s official opportunity page states that the 2026 opportunity will be open for one round only; it does not announce a later round. This page is therefore a historical reference to the closed cycle, not an invitation to apply.

NHMRC’s official September 2026 tracker records the closing time as 5:00 p.m. Australian Eastern Standard Time on 16 September 2026, and the minimum-data deadline as 5:00 p.m. on 19 August 2026. Both dates have passed. The tracker also explains that only applicants who completed the minimum data by its due date could submit a full application. No late or new submission can be made through this cycle.

NHMRC administered the grant on behalf of the Australian Government Department of Health, Disability and Ageing. The Department’s official announcement said up to AUD 13 million would be available for the opportunity. The grant opportunity guidelines linked from NHMRC set a per-grant ceiling of AUD 3 million, no minimum award, and a maximum project period of seven years. Those figures describe the closed 2026 competition; they should not be treated as current funding terms for any later call. The NHMRC opportunity page remains the official program record and links to GrantConnect materials.

Key details

Detail2026 cycle record
OpportunityMRFF Clinical Trials Activity Initiative: 2026 International Clinical Trial Collaborations Grant Opportunity
Grant numberGO8232
Funder and administratorAustralian Government Department of Health, Disability and Ageing; administered by NHMRC
FundingUp to AUD 3 million per grant; up to AUD 13 million for the opportunity
Grant periodUp to seven years
Minimum data deadline5:00 p.m. AEST, 19 August 2026 (passed)
Application close5:00 p.m. AEST, 16 September 2026 (closed)
Application systemNHMRC Sapphire, with institutional certification and submission by a Research Administration Officer
StatusOne-round 2026 opportunity; NHMRC has not announced another round on the official page

The funding ceiling was not an automatic award. The guidelines required requests to be appropriate to the proposed study, Australian delivery plan, eligible direct costs, and duration. Applicants needed to show that the requested amount could support the work plan and produce the stated outcomes. The total opportunity allocation and individual-grant limit were separate figures: the former applied across awards, while the latter capped any one grant.

Status and how to read this archive

This entry retains the closed cycle’s published requirements so that research offices and trial teams can understand what GO8232 sought and compare it with future calls if one is announced. It does not suggest that Sapphire is accepting GO8232 submissions, that the earlier application window can be reopened, or that any later competition will repeat the same terms. The official NHMRC page is the place to check for an amendment or future announcement. As of the review timestamp in the front matter, that page says the 2026 program was for one round only and gives no date for another round.

What the grant is designed to support

The Clinical Trials Activity Initiative is intended to increase clinical trial activity in Australia, strengthen the evidence base for clinical care, and help patients access trials that are relevant to their health circumstances. GO8232 applies that purpose to international collaboration. Its two stated objectives are to promote Australian involvement in international collaborative investigator-initiated clinical trials through the establishment and coordination of Australian trial sites, and to generate high-quality evidence about novel health treatments, drugs, or devices in usual-care settings.

There are two practical collaboration models. An Australian team may lead an international trial and use MRFF support for overarching coordination of sites in Australia and overseas, together with one or more Australian sites. Alternatively, an Australian team may join a trial initiated by international partners and use the grant to coordinate the Australian contribution and run one or more Australian sites. In both models, the proposal needs a credible division of responsibilities rather than a generic statement that overseas partners will participate.

The guidelines particularly encourage collaborations that make a trial feasible when an Australia-only study would be difficult. Examples include low-prevalence conditions or questions requiring a large participant pool to detect meaningful differences. If that rationale applies, the applicant is expected to show how the international design will be used. The guidelines say it is reasonably expected that the total participant number will be at least double the number recruited through Australian sites in such cases.

Novelty can include an innovative application of an existing intervention. The call also encourages novel trial methodologies and use of established clinical quality registries. Pre-clinical studies, phase I and phase II trials, post-market monitoring, and extensions of ongoing clinical trials are outside the stated fit. Most importantly, recruitment at the Australian trial site or sites must not have commenced when the proposal is made.

Who can apply and who should lead

The applicant must be an MRFF Eligible Organisation approved by NHMRC. Joint applications are encouraged, but there must be an eligible lead organisation that is the main driver of the project and will enter into the Commonwealth grant agreement if the application succeeds. The organisation may work with universities, medical research institutes, hospitals, government bodies, companies, charities, consumer organisations, health-care providers, and professional groups, provided the partnership makes sense for the proposed trial.

The team must nominate a Chief Investigator A (CIA). The CIA leads completion of the application, conducts the research, and carries reporting responsibilities under the grant agreement. Up to 15 Chief Investigators can be included. A person cannot be named as a Chief Investigator on more than one application to this opportunity; if that happens, both applications are ineligible. A CI does not need to hold a postgraduate qualification, although the team must collectively demonstrate the relevant clinical, scientific, operational, governance, and translation capability.

The CIA is generally required to be an Australian citizen or permanent resident at submission. A non-citizen or non-permanent resident may be able to serve as CIA if the required work visa is in place when the grant is accepted, but the CIA must be based in Australia during the grant period apart from reasonable overseas travel. Researchers who do not meet the CIA residency condition may still be eligible to participate as another CI.

The international partners need more than a name on a team list. The assessment criteria ask applicants to demonstrate that overseas partners have the clinical research experience and expertise needed for the proposed trial, that they are committed to the work, and that cooperative arrangements and effective working relationships are in place. Overseas sites must be supported by the international partners or other funding sources. Evidence of that support must be provided before MRFF funding begins.

What the funding can pay for

The budget should be built around direct project needs. Eligible cost categories include equipment, Personnel Support Packages, and other direct research costs. Direct costs may include clinical services above standard care, reasonable trial-related patient expenses, imaging and diagnostic services, project-specific equipment, research facility services, specialist computing, contract staff, and appropriate consumer involvement costs. Personnel requests should match the roles, responsibilities, and percentage of time actually needed.

Australian activity should be the centre of the budget. The guidelines allow funding for research activities in any Australian location and may allow a necessary overseas component when the required equipment or resource is not available in Australia and the activity is critical to completion. Overseas expenditure, including overseas travel, is generally limited to 10 percent of the total grant and must be documented and justified. Funding cannot be used to support overseas trial sites as a standalone activity or to recruit an overseas patient cohort for unrelated research.

The opportunity does not pay indirect research costs such as organisational overheads, general administration, routine infrastructure, ordinary computers and communications, furniture, patent costs, or standard ethics approval costs. It also cannot cover retrospective costs, duplicate a project already funded for the same purpose, or extend an ongoing clinical trial where Australian recruitment has already started. A detailed annual budget and justification are part of the value-and-risk assessment, so the request should be traceable to the work plan and milestones.

Application process and required materials in the closed cycle

Applications for GO8232 were made electronically through NHMRC’s Sapphire system. The lead applicant had to be an MRFF Eligible Organisation approved by NHMRC. Applications could be collaborative, but an eligible lead organisation was responsible for the submission and, if funded, the Commonwealth grant agreement. A Research Administration Officer (RAO) certified and submitted the application; the investigator team could not replace that institutional step.

The cycle used a minimum-data gate before the final application deadline. The minimum data was due by 5:00 p.m. AEST on 19 August 2026, according to NHMRC’s official tracker. It included an application title, eligible organisation, priority-population response, project synopsis, privacy agreement, research classifications, peer-review areas, keywords, and complete CIA details. NHMRC’s tracker cautioned that placeholder text could make an application ineligible and that applicants who did not complete minimum data by the due date could not submit the full proposal. This was a prerequisite within the closed cycle, not a remaining step for prospective applicants.

A complete application used the prescribed Grant Proposal template and Sapphire reports, and required institutional certification. The materials included a Declaration of Applicant Interests and relevant letters of support; facility letters were needed where applicable. The proposal covered the rationale and impact, methodology, milestones and performance indicators, investigator capability, risk management, cash and in-kind contributions, consumer involvement, measures of success, and references. Applicants had to follow the form’s formatting, file-size, and page requirements in force for that round.

Partner documentation mattered because this was an international collaboration scheme, not simply an Australian study with overseas names attached. Letters of support were expected to describe each organisation’s role, relevant sites, authorised contact, and cash or in-kind contribution. Overseas trial sites needed support from international partners or another funding source. Applicants also had to make the responsibilities for protocol leadership, site coordination, data, governance, and financial contributions understandable to reviewers. The RAO confirmed that the participating organisations had agreed on grant-management arrangements.

The final submission deadline recorded by NHMRC was 5:00 p.m. AEST on 16 September 2026. The grant guidelines, linked from the official NHMRC page through GrantConnect, remain the source for detailed form instructions and eligibility conditions from this cycle. If a future opportunity is announced, applicants should use its own guidelines and dates rather than assume the 2026 package is unchanged.

Closed-cycle timeline and planning lessons

NHMRC recorded the two hard dates for GO8232 as 19 August 2026 for minimum data and 16 September 2026 for the complete application. The first date was a gate: late completion of the narrative could not make up for missing minimum data. Teams preparing that cycle therefore needed Sapphire access, a selected eligible lead organisation, investigator records, classifications, and a sufficiently specific synopsis before the minimum-data cutoff. These are lessons from the completed round, not active deadlines.

The official NHMRC page says that the 2026 grant opportunity was open for one round only. Since the application close has passed and the page does not announce another round, there is no verified upcoming GO8232 deadline to report. Do not infer one from the prior calendar, the duration of funded projects, or the opening of a differently numbered clinical-trials opportunity. Any new scheme or round would need its own official announcement and guidelines.

For future planning, a trial team considering a comparable call can use the old process as a checklist of work that often needs institutional lead time: confirm the organisation’s eligibility, align international roles, establish whether Australian sites have begun recruitment, agree a protocol and recruitment plan, involve consumers, prepare direct-cost justifications, and secure partner letters. It should then verify whether a later call has materially different eligibility, dates, templates, caps, or assessment rules before relying on any of those historic details.

How applications will be assessed

Project Impact carries a 40 percent weighting. A strong response should connect the trial question to a specific health need, show how it builds on existing knowledge, and explain how results could improve Australian health outcomes, practice, or policy. It should also show how consumers, carers, communities, health providers, and other end users shaped the question and planned translation. Work involving a priority population should explain cultural acceptability, leadership, and meaningful involvement of that population.

Project Methodology carries 30 percent. Reviewers will look for a scientifically sound and feasible project plan, including the trial design, participants, intervention and comparator where relevant, recruitment targets, diversity, statistical approach, data use, governance, milestones, and performance indicators. The application must address how sex, gender, variations of sex characteristics, and sexual orientation are integrated into the research or provide a reasoned explanation for why specific variables are not relevant.

Capacity, Capability and Resources carries the remaining 30 percent technical weighting. The team should show the mix of clinical, scientific, project-management, trial-operations, consumer, and translation skills needed to deliver the work. International partners should have a clear role and evidence of commitment. A long publication list is less persuasive than a concise record of relevant impact, trial delivery, service or policy change, and the ability to manage the proposed international structure.

The fourth criterion, Overall Value and Risk of the Project, is non-weighted but still decisive. It considers the Measures of Success statement, budget, contributions, and risk plan. To receive funding, an application must reach at least a satisfactory score on every criterion: the guidelines specify a score of 4 or higher on each weighted technical criterion and a Good or Excellent rating for the overall value-and-risk criterion. Applications rated Excellent on overall value and risk are prioritised, with technical scores then used to further prioritise proposals.

Preparation advice and common mistakes

Start with the Australian decision the trial could inform. A proposal that only describes an international protocol may not explain why Australian sites, patients, health services, or policy makers need the evidence. State the clinical or health-system gap, identify the Australian contribution, and show how the trial results could be used in usual care. Tie each proposed cost and milestone to that chain of logic.

Do not treat partnership as an afterthought. Confirm who owns the protocol, who coordinates which sites, who pays for overseas work, how data and governance will operate, and what happens if recruitment or regulatory approvals fall behind. A signed or otherwise credible partner commitment is stronger than a statement that discussions are underway.

Avoid presenting an unstarted concept as a ready-to-submit trial. The guidelines expect a detailed concept design and cooperative arrangements before application. At the same time, do not claim that an Australian site is eligible if it has already begun recruiting. Check the recruitment status in writing across all proposed Australian sites.

Budget conservatively. A request close to the AUD 3 million ceiling is not inherently stronger. Explain personnel effort, site services, patient-related direct costs, equipment, data work, consumer support, and any overseas spending. Keep indirect costs out, identify in-kind contributions accurately, and disclose other funding. False, incomplete, or misleading information can lead to exclusion and may trigger research-integrity consequences.

Finally, make the proposal readable to more than one discipline. NHMRC says assessors may include scientific experts, consumers, industry experts, health-service providers, and international reviewers. Define technical terms, make the benefit to Australian patients visible, and use milestones that a reviewer can test: ethics approval, first participant, recruitment rate, site performance, budget progress, data outputs, trial close-out, and publication or implementation steps.

Frequently asked questions

Can a research team outside Australia apply directly?

Not as the lead applicant for this opportunity. The application must be made through an MRFF Eligible Organisation approved by NHMRC, with the CIA based in Australia under the stated conditions. International researchers can participate as CIs or partners when the collaboration and Australian trial activity are clear.

Does the grant fund the entire international trial?

No. It can fund the Australian-based components of a multinational clinical trial and, in the appropriate model, Australian coordination of international activity. Overseas trial sites must have support from international partners or another source, and overseas expenditure is generally limited to 10 percent of the grant.

Is AUD 3 million guaranteed to every successful project?

No. AUD 3 million is the maximum for one grant. There is no minimum award, and applicants should request an amount appropriate to the work, duration, and eligible costs. The total opportunity had up to AUD 13 million available across the closed cycle.

Is there a current deadline or a new round?

No upcoming GO8232 deadline is listed on NHMRC’s official opportunity page. The 2026 round closed at 5:00 p.m. AEST on 16 September 2026, after its minimum-data cutoff on 19 August 2026. NHMRC says the 2026 opportunity was open for one round only. This entry keeps those dates as historical facts; it does not predict a new round.

Where are the official historical documents?

The NHMRC GO8232 opportunity page provides the official overview and the link to GrantConnect materials for the closed cycle. NHMRC’s published tracker confirms the dates shown here. The linked guidelines and templates are the appropriate sources for interpreting the 2026 rules. A later round, if announced, may have different material and should be checked separately.

  1. NHMRC MRFF International Clinical Trial Collaborations Grant Opportunity (GO8232) — official overview and GrantConnect link.
  2. NHMRC funding calendar — opening, minimum-data, and closing dates.
  3. Australian Government Department of Health and Aged Care: $13 million for international clinical trials in Australia — policy context and total funding announcement.
  4. NHMRC Research Help Centre — questions should be routed through the MRFF Eligible Organisation’s Research Administration Officer.

This archive is useful for understanding the scope and mechanics of the completed GO8232 cycle: it sought international investigator-initiated trials with a defined Australian role, eligible institutional leadership, partner commitments, and an evidence-based plan for clinical impact. Teams looking for funding should first confirm whether NHMRC or the Australian Government has published a new opportunity. The closed-cycle dates and conditions above remain historical context and are not a substitute for a future call’s own rules.

Next step
Check official source